SLG
RDY icon

Stanley-Laman Group’s Dr. Reddy's Laboratories RDY Stock Holding History

Stanley-Laman Group’s Portfolio RDY Stock Details RDY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-140,000
Closed -$1.85M – 303
2025
Q1 		$1.85M Buy
+140,000
New +$1.93M 0.28% 129

Other funds holding RDY

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $70.2B AUM 29.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AIM
Aikya Investment Management London, United Kingdom $345M AUM 10.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stanley-Laman Group's RDY Position: Q2 2025 in Review

Stanley-Laman Group sold out of Dr. Reddy's Laboratories (RDY) in Q2 2025, closing a stake of 140,000 shares — an estimated $1.85M sold.

Stanley-Laman Group first reported a position in RDY in Q1 2025 and held it in 1 quarter. The position peaked at $1.85M in Q1 2025. 242 funds tracked by Wall St. Rank hold RDY as of Q2 2025.

  • Stanley-Laman Group reported no remaining Dr. Reddy's Laboratories position as of Q2 2025 after selling out during the quarter.
  • Stanley-Laman Group sold 140,000 Dr. Reddy's Laboratories shares in Q2 2025, an estimated $1.85M.
  • Stanley-Laman Group first reported a position in Dr. Reddy's Laboratories in Q1 2025 and held it in 1 quarter.
  • Stanley-Laman Group's Dr. Reddy's Laboratories position peaked at $1.85M in Q1 2025.
  • 242 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q2 2025.

Based on Stanley-Laman Group's 13F filing for Q2 2025, filed 29 Jul 2025.